Shares of Indivior Plc (NASDAQ: INDV) rose 15.5% following the release of strong third-quarter results and an upgrade in full-year guidance. The company’s “Indivior Action Agenda” is successfully driving sales growth for its key medication, Sublocade, which is designed for moderate to severe opioid use disorder. Unlike traditional buprenorphine, Sublocade offers a monthly dosage, enhancing convenience for patients. This momentum positions Indivior as a profitable and cash-generative enterprise.
